PR Newswire
OSLO, Norway, March 12, 2021 /PRNewswire/ —
FINANCIAL YEAR 2020
- 22.03.2021 – Extraordinary General Meeting
- 26.03.2021 – Annual Report
FINANCIAL YEAR 2021
- 28.04.2021 – Annual General Meeting
- 26.05.2021 – Quarterly Report – Q1
- 27.08.2021 – Half-yearly Report
- 18.11.2021 – Quarterly Report – Q3
For further information, please contact:
IR enquiries
Malene Brondberg, CFO
Cell: +44 7561 431 762
Email: [email protected]
Media Enquiries
Mark Swallow/Frazer Hall/David Dible (Citigate Dewe Rogerson)
Tel: +44 203 926 8535
Email: [email protected]
About Nordic Nanovector:
Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers. Nordic Nanovector’s lead clinical-stage candidate is Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to advance the treatment of non-Hodgkin’s lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 26 billion by 2028. Nordic Nanovector retains global marketing rights to Betalutin® and intends to actively participate in the commercialisation of Betalutin® in the US and other major markets.
Further information can be found at www.nordicnanovector.com.
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/nordic-nanovector/r/nordic-nanovector-asa–financial-calendar,c3305287
View original content:http://www.prnewswire.com/news-releases/nordic-nanovector-asa-financial-calendar-301246301.html
SOURCE Nordic Nanovector
